Heng Mei

40PUBLICATIONS
36CO-AUTHORS
Cancer therapy (excl. chemotherapy and radiation therapy)Decision makingApplied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Genetics not elsewhere classifiedMolecular targets
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (40)

|Oct 06, 2026
Extended follow-up of in vivo BCMA CAR-T therapy in relapsed/refractory multiple myeloma.

|Aug 06, 2026
Machine Learning-Based Prediction of Mononuclear Cell Collection Efficiency for CAR-T Manufacturing.

|Jul 25, 2026
High IL-10 levels during CRS are negatively associated with NK-cell recovery after CAR-T cell therapy.

|Jul 24, 2026
BCMA-directed CAR T-cell therapy induces durable drug-free remission in refractory primary immune thrombocytopenia.

|Jul 14, 2026
Subsequent CAR-T and engineered antibody for relapsed/refractory multiple myeloma following BCMA-targeted treatment: a systematic review and meta-analysis.

|Apr 06, 2026
Efficacy and Safety of Subcutaneous Efgartigimod PH20 in Adults With Primary Immune Thrombocytopenia (ADVANCE SC): A Multicenter, Randomized, Double-Blinded, Placebo-Controlled, Phase 3 Trial.

Nichola Cooper, Catherine M Broome, Yoshitaka Miyakawa

Pageof 7

Frequent Collaborators

17 joint publications

Yu Hu

3 joint publications

Huiwen Jiang

3 joint publications

Chenggong Li

2 joint publications

Fengjuan Fan